Introduction {#s0005}
============

The respiratory tract is a major portal of entry for pathogenic organisms; infections at this site are the most common afflictions of humans. Children contract up to half a dozen respiratory illnesses each year, adults perhaps two or three, and most of these are caused by viruses. Though trivial colds and sore throats account for the majority of respiratory disease, their impact on communities is significant; millions of lost working hours and a considerable proportion of all visits to family physicians can be attributed to this type of infection. More serious lower respiratory tract infections tend to occur at the extremes of life, and in those with pre-existing pulmonary conditions. The most important human respiratory viruses are influenza and respiratory syncytial viruses (RSV), the former killing mainly the aged and the latter the very young. Of the estimated 5 million deaths from respiratory infections in children annually worldwide, at least one million are viral in origin.

Altogether, there are over 200 human respiratory viruses, falling mainly within six families: orthomyxoviruses, paramyxoviruses, picornaviruses, coronaviruses, adenoviruses and herpesviruses (see corresponding entries elsewhere in this text). Here we shall confine ourselves to those that enter the body via the respiratory route and cause disease confined largely to the respiratory tract. Many other 'respiratory' viruses become disseminated via the bloodstream to produce a more generalized disease, as is the case with most of the human childhood exanthems such as measles, rubella and varicella, or rinderpest and foot-and-mouth disease in cattle. Yet other viruses, entering by nonrespiratory routes, can reach the lungs via systemic spread, and pneumonia may represent the final lethal event, e.g. in overwhelming infections with herpesviruses or adenoviruses in immunocompromised neonates or patients with the acquired immune deficiency syndrome (AIDS).

Epidemiology {#s0010}
============

By definition, respiratory viruses are transmitted via the respiratory route. Virions are shed from the respiratory tract of an infected human or animal, particularly during sneezing, coughing, talking or barking. A sneeze generates an aerosol comprising up to a million tiny droplets less than 10 μm in diameter that quickly evaporate to yield droplet nuclei which remain suspended in the air for several minutes. This particulate material containing virions transmits infection following inhalation by someone nearby. Larger droplets (up to 100 μm) contain more virions but fall to ground within seconds. They are a danger to anyone directly in the line of fire. Alternatively, respiratory infections can spread by direct contact, e.g. kissing, or by transfer of nasal or oral secretions via hands to nose or mouth. At the height of a common cold such secretions are particularly copious and readily find their way on to handkerchiefs, towels, toothbrushes, eating utensils, doorknobs and so on, as well as hands.

Enveloped viruses such as orthomyxoviruses, paramyxoviruses and coronaviruses tend to be rather susceptible to inactivation by desiccation or by summer temperatures, but icosahedral viruses such as adenoviruses and picornaviruses are more stable; for example, certain outbreaks of foot-and-mouth disease have been attributed to virus carried in the wind for 100 km.

We associate respiratory infections with cold, wet weather but there is no evidence that the winter incidence of the common cold, or indeed any other respiratory disease, is attributable to cold or wet *per se*. Colds are not common in Arctic or Antarctic explorers, for example. It seems more likely that the striking winter peaks of respiratory disease caused by influenza and RSV ([Fig. 1](#f0005){ref-type="fig"}) are a reflection of our predilection during that season for avoiding the invigorating outdoor climate and shutting ourselves away in ill-ventilated centrally-heated buildings and vehicles, in close apposition to others of like mind. This hypothesis is supported by the observation that in the tropics, where summer and winter are replaced by 'wet' and 'dry' seasons, respiratory infections are more prevalent during the monsoonal rains when people spend more time indoors, exchanging parasites in crowded, often squalid conditions. An additional factor in the less developed world is the domestic air pollution (smoke) generated by the ever-present fire, lit for cooking and warmth inside poorly ventilated huts. Outbreaks of influenza often occur in boarding schools, army camps, nursing homes, etc.; similarly, nosocomial spread of RSV is common in hospital nurseries. Livestock such as cattle are particularly vulnerable when crowded together in feed-lots or transport vehicles, e.g. shipping fever. Figure 1Epidemic occurrence of influenza A and respiratory syncytial viruses. The histograms show the monthly isolations of these two viruses from patients admitted to the Fairfield Hospital for Infectious Diseases, Melbourne, over the periods indicated. Compare the regular winter epidemics of RSV (causing significant disease mainly in infants) with the less regular winter epidemics of influenza. There were major peaks of influenza in 1957 (first appearance of the new human influenza subtype H2N2, known as 'Asian flu') and then again in 1968 (marking the emergence of the novel subtype H3N2, known as 'Hong Kong flu'). (Data courtesy of Drs A. A. Ferris, F. Lewis and I. D. Gust. From Fenner F and White DO (1976) *Medical Virology* 2nd edn. New York: Academic Press.)

Respiratory viruses spread with great facility and speed, albeit not with the explosive onset that characterizes certain 'common source' outbreaks of enteric viruses when feces contaminate food or water supplies. First, respiratory diseases have a very short incubation period, usually 2--7 days. Second, very large numbers of virions (10^3^--10^9^ per ml of respiratory secretions) are shed, commencing even before symptoms develop, and peaking around the time the patient is coughing or sneezing with greatest abandon. A single infectious particle may infect a susceptible contact. Typically, a young child picks up the latest virus at school, brings it home and passes it on to the rest of the family and perhaps to the neighbours' children. Within 2 or 3 months up to half the population of a city may have contracted the infection and developed immunity to the virus. As the proportion of uninfected susceptibles in the community falls, the epidemic burns itself out ([Fig. 1](#f0005){ref-type="fig"}).

Respiratory viruses may evolve quite rapidly in the field. RNA viruses in particular display a very high rate of mutation, because their RNA polymerase is error prone and lacks the error-correcting capability that accompanies DNA replication. Any spontaneously arising mutant that is capable of replicating in the presence of antibody against the wild-type virus will have a growth advantage. Eventually mutants emerge that contain amino acid substitutions in most or all of the immunodominant antigenic domains on the critical surface protein of the virion. Such multiple mutants, no longer neutralizable by wild-type antibody, are designated a new strain and may initiate another epidemic. This phenomenon is known as antigenic drift. While best characterized for influenza, it is presumably the mechanism that has also given rise to the dozens of known serotypes of rhinoviruses, enteroviruses, adenoviruses, and so on. A second, more dramatic type of change, known as antigenic shift, is observed in RNA viruses with segmented genomes that can undergo genetic reassortment. Novel subtypes of human influenza A viruses, capable of initiating pandemics that can infect the majority of the world's population within a year, arise every generation or so as a result of reassortment following co-infection of, say, a pig with a human and an avian influenza virus simultaneously.

Pathogenesis and Immunity {#s0015}
=========================

Inhaled droplets of more than 10 μm in diameter are trapped in the turbinates of the nose ([Fig. 2](#f0010){ref-type="fig"}), whereas those measuring 5--10 μm often reach the trachea and bronchioles. Many of these particles become trapped in the layer of mucus that blankets the ciliated epithelium and are carried by ciliary action to the pharynx, where they are swallowed or coughed out. Smaller particles still can be inhaled directly into the lung and some may reach the alveoli. Here, virus may be phagocytosed and destroyed by alveolar macrophages (although some viral species undergo an abortive cycle of replication and others have developed the capacity to replicate in macrophages). A few virions will succeed in attaching to susceptible epithelial cells via the appropriate ligand--receptor pairing and thereby initiate infection. Progeny virions will be released a few hours later, often by budding from the apical surface of the cell into the lumen of the respiratory tract, and then initiate a second cycle of infection in adjacent or more distant cells. Some of the enveloped species of respiratory viruses are dependent upon a particular cellular protease to cleave the appropriate viral envelope glycoprotein, e.g. influenza HA, or RSV F protein, otherwise the progeny are noninfectious. Moreover, mucus contains glycoprotein inhibitors which can neutralize the infectivity of certain viruses, e.g. influenza. Mannose-binding lectins such as those in lung surfactant can also neutralize virus. Interferon, synthesized by and secreted from virus-infected cells, binds to interferon receptors on nearby uninfected cells and protects them by inhibiting viral replication. Figure 2(**A**) Pathways of infection and mechanical protective mechanisms in the respiratory tract. On the right, clinical syndromes produced by infection at various levels of the respiratory tract. (**B**) Section of the turbinates (X---X) magnified 2.5 times, showing the narrow and complicated pathway of inspired air, and thus the ease with which slight swelling 'blocks the nose'. (From [@bib5], as modified from [@bib4]*Viral Pathogenesis and Immunology.* Oxford: Blackwell Scientific.)

If specific neutralizing antibodies of the IgA class are already present in the mucus coating the respiratory tract as a result of previous infection or vaccination, they will bind to the corresponding epitopes on the surface of the virion and neutralize its infectivity by blocking attachment or fusion of viral envelope with plasma membrane or endocytic vesicle, thus preventing uncoating of the viral genome. In the absence of pre-existing antibody, however, infection can progress because primary antibody synthesis does not become significant for several days. Additional mechanisms are brought into play to control viral replication during this early period, with the first cells to be mobilized being the natural killer (NK) cells from bone marrow, which become activated by interferon (IFN) to lyse virus-infected cells. Shortly thereafter, the relevant clones of T lymphocytes are activated. Helper T (Th) cells (CD4+) recognize peptides generated from endocytosed virions by proteolysis and presented in the peptide-binding groove of the class II major histocompatability complex (MHC) molecules on the surface of antigen-presenting cells (dendritic cells and macrophages) and are triggered to proliferate and to secrete a range of lymphokines that mediate inflammation by attracting macrophages and other leukocytes to the site, and by upregulating macrophages, B cells and T cells. Cytotoxic T cells (CD8+), on the other hand, see endogenous viral peptides generated by proteolysis of newly synthesized viral proteins and bound to class I molecules on the surface of infected cells.

A major mechanism of recovery from viral infection is lysis of infected cells by activated CD8+ T lymphocytes, preferentially but not exclusively by a perforin/granzyme-mediated process. Children with a congenital T cell deficiency may die from measles or RSV infection; conversely, influenza virus-infected athymic mice may be saved by adoptive transfer of virus-specific CD8+ T cells. CD4+ T cells also contribute to the process of recovery by secretion of cytokines such as IFN-γ and through provision of help to B cells in the developing humoral response. Specific antibodies may act by (1) neutralizing virus, (2) complement-mediated lysis of infected cells, or (3) antibody-dependent cell-mediated cytolysis (ADCC). In addition, IgA, during its active passage through respiratory epithelial cells, may combine with viral proteins produced within these cells, resulting in reduced output of infectious progeny.

Whereas the immune response to respiratory infection is instrumental in recovery, it can also, paradoxically, exacerbate the disease itself. CD4+ Th1 cells may induce such a strong inflammatory response (delayed-type hypersensitivity or DTH) as to cause lethal consolidation of the lung (pneumonia). Furthermore, responses orchestrated by the type 2 cytokines IL-4 and IL-5, namely IgE production and eosinophil degranulation, can precipitate a life-threatening attack of asthma in a young infant infected with RSV. Other factors may also contribute to RSV bronchiolitis: virus infection not only enhances bronchial reactivity to antigen but also destroys the ciliated epithelial cells responsible for mucociliary clearance, thus allowing the infant's narrow bronchioles to become plugged with mucus, inflammatory cells and necrotic cell debris, while bronchoconstriction may also be triggered by vagal nerve reflexes or by release of mediators by inflammatory cells. Blockage of airways causes hypoxia and a pathophysiologic cascade that leads to acidosis and uncontrollable fluid exudation into airways.

Superinfection with bacteria, typically *Streptococcus pneumoniae, Haemophilus influenzae* or *Staphylococcus aureus,* often complicates viral pneumonitis, and without chemotherapy can lead to a fatal outcome. The very young and very old are particularly at risk, as are the immunocompromised, and premature or malnourished infants.

Systemic viral infections such as measles generate a strong memory response and prolonged production of IgG antibodies, which protect against reinfections for life. In contrast, viruses that cause infection localized to the respiratory tract, with little or no viremia, e.g. RSV or rhinoviruses, induce only a relatively short-lived mucosal IgA antibody response, and reinfections with the same or a somewhat different strain can recur repeatedly throughout life. In addition, numerous strains arising by antigenic drift may cause sequential episodes of the same disease in a single individual.

Viral Diseases of the Human Respiratory Tract {#s0020}
=============================================

While some viruses have a predilection for one particular part of the respiratory tract, most are capable of causing disease at any level and the syndromes to be described below overlap somewhat ([Fig. 3](#f0015){ref-type="fig"}). Nevertheless, for ease of description we will designate six basic diseases of increasing severity as we descend the respiratory tract: rhinitis, pharyngitis, croup, bronchitis, bronchiolitis and pneumonia ([Table 1](#t0005){ref-type="table"}). Figure 3Frequency with which particular viruses produce disease at various levels of the human respiratory tract. (Data courtesy of Dr D. A. J. Tyrrell. From [@bib5].)Table 1Human respiratory viral diseases*VirusDiseaseCommonLess common*Rhinitis (common cold)RhinovirusesRSV, parainfluenza, influenzaCoronavirusesAdenovirusesCoxsackie A21, 24; echo 11, 20PharyngitisParainfluenza 1--3RhinovirusesInfluenzaAdenoviruses 1--7Herpes simplexRSVEB virusCytomegalovirusCoxsackie ALaryngotracheobronchitis (croup)ParainfluenzaRSVInfluenzaBronchiolitisRSVInfluenzaParainfluenza 3PneumoniaRSVAdenoviruses 3, 7Parainfluenza 3CytomegalovirusInfluenzaMeaslesVaricella

Rhinitis (common cold) {#s0025}
----------------------

The classical common cold (coryza) is marked by copious watery nasal discharge and congestion, sneezing, and perhaps a mild sore throat or cough, but little or no fever. Rhinoviruses are the major cause, several serotypes being prevalent all year round and accounting for about half of all colds. Coronaviruses are responsible for about another 15%, mainly those occurring in the winter months. Certain enteroviruses, particularly coxsackieviruses A21 and A24, and echoviruses 11 and 20 cause febrile colds and sore throats in the summer. In children, RSV, parainfluenza viruses and the lower-numbered adenoviruses are between them responsible for up to half of all upper respiratory tract infections (URTI or URI).

Otitis media or sinusitis sometimes complicate URI. Bacterial superinfection is generally involved, but viruses have also been recovered from the effusion. Respiratory infections with RSV, influenza, parainfluenza, adenovirus or measles viruses predispose to otitis media. Indeed, repeated viral infections can precipitate recurrent middle ear infections, leading to progressive hearing loss.

Pharyngitis {#s0030}
-----------

Most pharyngitis is of viral etiology. URI with any of the viruses just described can present as a sore throat, with or without cough, malaise, fever and/or cervical lymphadenopathy. Influenza, parainfluenza and rhinoviruses are common causes throughout life, but other agents are prominent in particular age groups: RSV and adenoviruses in young children; herpesviruses in adolescents and young adults. Adenoviruses, though not major pathogens overall, are estimated to be responsible for about 5% of all respiratory illnesses in young children, often presenting as pharyngoconjunctival fever. Primary infection with herpes simplex virus (HSV), if delayed until adolescence, presents as a pharyngitis and/or tonsillitis rather than as the gingivostomatitis seen principally in younger children; the characteristic vesicles, rupturing to form ulcers, can be confused only with herpangina, a common type of vesicular pharyngitis caused by coxsackie A viruses. Infectious mononucleosis (glandular fever) is usually marked by a very severe pharyngitis, often with a membranous exudate, together with cervical lymphadenopathy and fever; this syndrome is generally caused by Epstein--Barr (EB) virus in 15--25-year-olds, and less commonly by cytomegalovirus.

Laryngotracheobronchitis (croup) {#s0035}
--------------------------------

Croup is one of the serious manifestations of parainfluenza and influenza virus infections. A young child presents with fever, cough, inspiratory stridor and respiratory distress, sometimes progressing to complete laryngeal obstruction and cyanosis. Parainfluenza viruses are responsible for about half of all cases, type 1 being more common than type 2. Influenza and RSV are important causes during winter epidemics.

Bronchitis {#s0040}
----------

Influenza, parainfluenza and RSV are the main viral causes of acute bronchitis. There is also evidence that chronic bronchitis, which is particularly common in smokers, may be exacerbated by acute episodes of infection with influenza viruses, rhinoviruses or coronaviruses.

Bronchiolitis {#s0045}
-------------

RSV is the most important respiratory pathogen during the first year or two of life, being responsible, during winter epidemics, for about half of all bronchiolitis in infants. Parainfluenza viruses (especially type 3) and influenza viruses are the other major causes of this syndrome. Breathing becomes rapid and labored, and is accompanied by a persistent cough, expiratory wheezing, cyanosis, a variable amount of atelectasis, and marked emphysema visible by x-ray. The disease can develop with remarkable speed and is one of the causes of sudden infant death syndrome (SIDS), where an infant may die overnight.

Pneumonia {#s0050}
---------

Whereas viruses are relatively uncommon causes of pneumonia in adults, they are very important in young children. RSV and parainfluenza (mainly type 3) are between them responsible for 25% of all pneumonitis in infants in the first year of life. Influenza also causes a considerable number of deaths during epidemic years. Adenoviruses 3 and 7 are less common but can be severe; long-term sequelae such as obliterative bronchiolitis or bronchiectasis may permanently impair lung function. Up to 20% of pneumonitis in infants has been ascribed to perinatal infection with cytomegalovirus (CMV). CMV may also cause potentially lethal pneumonia in immunocompromised patients, as may measles, varicella and adenoviruses. Moreover, viral pneumonia not uncommonly develops in adults with varicella, and in military recruits involved in outbreaks of adenovirus 4 or 7, while measles is often complicated by bacterial pneumonia, especially in malnourished children in Africa and South America. In the elderly, and particularly in those with underlying pulmonary or cardiac conditions, influenza is a major cause of death, either via influenza pneumonitis or more commonly via secondary bacterial pneumonia.

Viral pneumonitis often develops insidiously following URI and the clinical picture may be atypical. The patient is generally febrile, with a cough and a degree of dyspnea, and auscultation may reveal some wheezing or moist rales. Unlike typical bacterial lobar pneumonia with its uniform consolidation, or bronchopneumonia with its streaky consolidation, viral pneumonitis is usually confined to diffuse interstitial lesions. The radiological findings are not striking; they often show little more than an increase in hilar shadows or, at most, scattered areas of consolidation.

Space does not permit a discussion of veterinary diseases, but [Table 2](#t0010){ref-type="table"} lists some of the most important respiratory viral diseases of farm and companion animals. Most of these agents are relatively specific to a single animal species, or to closely related species, and do not infect humans. Influenza is occasionally transmitted to humans following close contact with pigs or birds infected with a swine or avian influenza virus respectively, but generally fails to spread beyond the first human case. At the time of writing an avian influenza strain has caused a small number of deaths in Hong Kong residents recently in contact with infected chickens. The greater danger in such a situation is the possibility of genetic reassortment occurring between the avian strain and a human strain already well adapted to human--human transmission. A recently discovered paramyxovirus, known as equine morbillivirus because it was responsible for the death from pneumonia of several racehorses as well as their well-known trainer, now appears to be native to Australian fruit-eating bats. Table 2Major respiratory viral diseases of animals*HostDisease(virus)Virus family*CattleInfectious bovine rhinotracheitis*Herpesviridae*CattleRespiratory syncytial virus*Paramyxoviridae*Cattle, swineFoot-and-mouth disease*Picornaviridae*HorseEquine rhinopneumonitis*Herpesviridae*CatFeline calicivirus*Caliciviridae*CatFeline rhinotracheitis*Herpesviridae*DogCanine laryngotracheitis*Adenoviridae*DogCanine distemper*Paramyxoviridae*ChickenInfectious laryngotracheitis*Herpesviridae*ChickenAvian infectious bronchitis*Coronaviridae*BirdsNewcastle disease*Paramyxoviridae*Birds, horses, swineInfluenza*Orthomyxoviridae*

Laboratory Diagnosis {#s0055}
====================

The etiology of respiratory viral infection can be established in the laboratory by identifying the virus itself, viral antigen or the viral genome. The most appropriate specimen is generally a throat swab or, better still, mucus aspirated from the nasopharynx, taken early in the disease. Because enveloped respiratory viruses with helical nucleocapsids are notoriously labile, the specimen is kept cold and moist, transported promptly to the laboratory and processed as soon as practicable.

Enzyme immunoassay (EIA) is the method of choice for the rapid detection of antigen in respiratory secretions. Diagnostic kits, based on appropriate monoclonal antibodies for antigen-capture and detection respectively, and often incorporating a biotin--avidin readout system, are now available for all common human respiratory viruses and many of the important animal pathogens. EIA is replacing immunofluorescence (application of fluorescein-labeled monoclonal antiviral antibody to infected cells aspirated from the throat). Multiple target (multiplex) polymerase chain reaction (PCR) for the amplification of the viral genome, followed by its identification using an appropriate nucleic acid probe, is fast becoming popular as a diagnostic technique for respiratory infections and in epidemiologic investigations.

Most of the known respiratory viruses can quite readily be cultivated in appropriate cell lines from the corresponding host species, e.g. diploid lung fibroblasts or HUT-292 cells for human viruses. Growth of the virus is detected by cytopathic effects and/or hemadsorption or immunofluorescence, and the virus recovered from the supernatant is then typed using any of a variety of serological techniques. However, this sequence is so time consuming and expensive that isolation and identification of virus is today undertaken mainly by reference laboratories requiring a large supply of the virus for further characterization, for research, or for antigen or vaccine production. Viral culture nevertheless remains a vital first step in the identification of agents responsible for newly emerging diseases.

'Serology', i.e. identification and quantification of antibody in the patient's serum, is also far too slow to be of value in influencing the management of the patient, hence it is used principally in seroepidemiological surveys to assess the immune status of populations. IgM-capture EIA does provide a rapid diagnosis but fills only a limited role in the routine diagnostic laboratory.

Vaccines and Chemotherapy {#s0060}
=========================

Very successful live attenuated vaccines are in general use against certain 'respiratory' viruses like measles, mumps and rubella, which, though naturally transmitted via the respiratory route, are absolutely dependent upon viremic spread to their target organs elsewhere in the body. In contrast, it is a much more challenging assignment to develop effective vaccines against viruses whose pathogenicity is essentially confined to the respiratory tract. The major reasons for this are that (1) secretory IgA memory is relatively short-lived, and (2) numerous antigenically distinct strains or serotypes are capable of causing the same clinical syndrome. Thus, a common cold vaccine might need to contain dozens of different serotypes of rhinoviruses (± coronaviruses). An inactivated vaccine is used to protect the aged and other risk groups against the currently prevalent strains of influenza, but its composition must be updated regularly to keep abreast of antigenic drift and shift and, even so, its efficacy in the aged is only of the order of 50--80%. The incorporation into vaccines of mucosal adjuvants, e.g. low-toxicity mutants or individual subunits of cholera toxin and *Escherichia coli* heat-labile toxin, is being examined in the hope of stimulating potent antiviral mucosal IgA responses. Improved antigen-delivery strategies, many of which utilize the size and multivalent antigen presentation properties of the viruses themselves, are also being investigated. Immunostimulatory complexes or 'ISCOMs', which are small adjuvant- and lipid-containing particles into which viral proteins can be inserted, already form the basis for an equine influenza vaccine. Live 'cold-adapted' mutants, for many years licensed as influenza vaccines in Russia, replicate only at the low temperature of the nose and are generally avirulent. Although it has proven difficult to walk the tightrope between genetic stability of avirulence on the one side, and adequate replication (hence immunogenicity) on the other, there is currently considerable interest in re-exploring the potential of such viral mutants for intranasal vaccination in other parts of the world. Another potentially exciting vaccine strategy is the use of recombinant DNA encoding the vaccine antigen, delivered in the form of a plasmid by syringe or 'gene gun'. Such vaccines, encoding the nucleoprotein and hemagglutinin of influenza A virus, have successfully elicited protective responses in animals. Subsequent efforts in this area include methods for enhancing the efficiency of transfection of host cells to increase the feasibility of application in humans.

In the long term another source of hope may lie with antiviral chemotherapeutic agents (see Antivirals), although significant barriers still remaining are (1) the multiplicity of viruses involved and the specific antiviral spectrum of available agents; (2) difficulties with drug delivery, efficacy and toxicity; (3) the fact that high titers of virus may be produced even before the onset of symptoms; and (4) emergence of drug-resistant mutants. Since the discovery of interferon in 1957, the field of antiviral chemotherapy has moved slowly. Although IFN-α is effective when given intranasally shortly before or after virus exposure, its use is not practical because of cost of production, frequency of doses required and problems with local bleeding and discharge. The only agents currently in use against respiratory viruses are (1) amantadine and its methylated derivative rimantadine, which display activity against influenza A if given prophylactically and act by interfering with the ion flux mediated by the M2 channel-forming protein of the virus, thereby inhibiting its uncoating; and (2) ribavirin, a nucleoside analogue, which may be of value in severely ill infants with RSV bronchiolitis/pneumonia when administered as a small-particle aerosol. More recently, thanks to x-ray diffraction and cryoelectron microscopy techniques, sites on viral proteins essential for interaction with the host cell receptor or otherwise critical to the infectious process can be visualized. From this has blossomed the age of computer-aided drug design for the development of antivirals. Among the compounds already in clinical trial are those that block the enzyme active site of influenza neuraminidase, a glycoprotein whose role is to facilitate the release of progeny virions from infected cells and prevent self-aggregation of the virus. Others target a small hydrophobic pocket within the canyon region of the coat proteins of rhinoviruses; these drugs stabilize the coat proteins, thereby preventing uncoating and release of viral RNA for replication. Viral mutants resistant to these drugs can be derived in the laboratory but their significance *in vivo* remains to be established.
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